Sutro Biopharma, Inc.
STRO
Last
$14.27
Day
-6.9%
1y
+79.2%
5y
-92.0%
52w
-65.1%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0526d
EMA 21
16.24
EMA 50
18.91
EMA 200
21.42
20d high
-12.0%
5y high
-93.5%
5y range
4th
Positions held
Your positionsSTRO isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-12
Hold
avoid
Signal
Sell
Target
$17.32
Stop
$13.65
Stop distance
4.3%
Target vs last
+21.4%
Fundamentals
| Market cap | $254.02M | Enterprise value | $100.46M | Trailing P/E | — | Forward P/E | -2.47 |
| PEG | — | Price / book | -2.46 | Beta | 1.50 | Dividend yield | 0.00% |
| Revenue growth | -84.6% | Earnings growth | — | Gross margin | -2.2% | Operating margin | -3.0% |
| Profit margin | 0.0% | ROE | — | ROA | -36.1% | Debt / equity | — |
| Current ratio | 3.32 | Free cash flow | -$100.76M | Analyst recommendation | strong_buy | Mean target | $47.23 |
| 52w high | $43.85 | 52w low | $7.15 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $9.8M | $14.5M | $11.6M | $9.7M | $63.7M | — |
| Op margin | -301.7% | -203.9% | -289.0% | -401.3% | 23.7% | — |
| Net income | -$38.5M | -$38.5M | -$46.8M | -$56.9M | -$11.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$29.7M | -$29.6M | -$33.7M | -$38.9M | $15.1M | — |
- Revenue -32% vs prior quarter ($9.8M vs $15M).
- Operating margin compressed to -301.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $102M | $62.0M | $154M | $67.8M | — |
| Op margin | -102.4% | -384.3% | -58.1% | -190.3% | — |
| Net income | -$191M | -$227M | -$107M | -$119M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$105M | -$238M | -$89.3M | -$129M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
2026-08-12 · STRO Stock Plummets 15% — What Drove The Selloff?
2026-08-12 · Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
2026-08-11 · Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
2026-08-07 · SpaceX upgraded, Trade Desk downgraded: Wall Street's top analyst calls
Price (daily)
Full chart · RSI · MACD · patternsSTRO · daily-5.0% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin